Conflict of interest
ONCOLOGY
EJ: reports research grants from Abbvie, Adaptive Biotechnologies, Amgen, Pfizer, and Takeda; and consultancy fees from Abbvie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Incyte, Novartis, Pfizer, and Takeda. NJS reports research grants from Takeda Oncology, Astellas Pharma, Xencor, and Stemline Therapeutics; consultancy fees from Pfizer and Jazz Pharmaceuticals; and honoraria from Novartis, Amgen, Sanofi, and BeiGene. NP reports research grants from Novartis, Stemline Therapeutics, Samus Therapeutics, Abbvie, Cellectics, Affymetrix/Thermo Fisher Scientific, Daiichi Sankyo, Plexxikon, MustangBio, honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, Abbvie, MustangBio, Roche Molecular Diagnostics, Blueprint Medicines, DAVA Pharmaceuticals, Springer Science+Business Media LLC, Aptitude Health, NeoPharm, CareDX, Consulting or advisory role in Blueprint Medicines, Pacylex Pharmaceuticals Inc., Immunogen, Mristol Myers Squibb, Clearview Healthcare Partners, Astellas Pharma US Inc., Protagonist Therapeutics, Triptych Health Partners, CTI BioPharma Corp and Travel/accommodation expenses from Stemline Therapeutics, Celgene, Abbvie, DAVA oncology, MustangBio. ND: reports research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen; and served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs, and Agios. HK: reports research grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi-Sankyo, Immunogen, Jazz, Novartis, and Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical, NOVA Research, Novartis, Pfizer, Precision Biosciences, and Taiho Pharmaceutical Canada. All other authors declare no competing interests. MA: reports research funding from AstraZeneca, Amgen, Daiichi Sankyo, Jazz, GlycoMimetics; consultancy fees from Amgen, AstraZeneca, Daiichi Sankyo, Syndax, GlycoMimetics, Oncoceutics, and Aptose; and holds stock from Reata, Oncoceutics/Chimerix and Aptose. CDD: reports research grants from Abbvie, Agios/Servier, Astex, Calithera, Celgene/BMS, Cleave, Daiichi-Sankyo, ImmuneOnc, Loxo; honoraria/consulting fees from Abbvie, Agios/Servier, Astellas, Celgene/BMS, Cleave, Foghorn, Genentech, Novartis, Notable Labs, Takeda.